Majumder Anusree, Jagani Rajat, Basu Atoshi
Graded Specialist (Pathology), Command Hospital (Southern Command), Pune 411040, India.
Commanding Officer, Armed Forces Transfusion Centre, Delhi 110010, India.
Med J Armed Forces India. 2020 Jan;76(1):63-70. doi: 10.1016/j.mjafi.2018.10.002. Epub 2019 Feb 26.
Basal-like breast cancer has an unfavorable prognosis. Immunohistochemically, they are predominantly estrogen receptor (ER), progesterone receptor (PR) and CerbB2 receptor (HER2)-negative, show expression of Cytokeratins (CKs) 5/6, CK14, CK 17 and P-cadherin and are associated with germline BRCA1 mutations. Immunohistochemistry (IHC) is an easily available and relatively inexpensive technique that can detect this cancer subtype, and patients can benefit from aggressive management protocols. The aim of this study was to evaluate the expression of CK 5/6 and CK14 in breast cancer and its correlation with age, tumor grade, tumor size, histomorphological pattern, nodal status, ER, PR, HER2/neu, and Ki-67 index.
Fifty treatment-naїve patients of breast carcinoma who underwent surgery constituted the study group. No core cut biopsy specimens were considered. Histopathological examination along with IHC was performed for CK5/6, CK14, ER, PR, HER2/neu, and Ki-67. Comparison between the expression of CK5/6 and CK14 with age, tumor size, tumor grade, histological subtype, nodal status, ER, PR, HER2/neu, and Ki-67 expression was performed using SPSS 20 version software.
Twenty-six percent of cases showed expression of CK5/6 and CK14. CK5/6 and CK14 expression correlated strongly with ER/PR negativity, young age, and Ki-67 proliferative index greater than 15%. No significant association with HER2/neu negativity was demonstrated. Contrasting results were obtained between CK5/6 and CK14 expression with respect to tumor grade and lymph node status.
IHC can be used to identify patients with basal phenotype breast cancer with good sensitivity and specificity, and such patients can benefit from aggressive management.
基底样乳腺癌预后不良。免疫组化显示,它们主要为雌激素受体(ER)、孕激素受体(PR)和CerbB2受体(HER2)阴性,表达细胞角蛋白(CKs)5/6、CK14、CK17和P-钙黏蛋白,且与种系BRCA1突变相关。免疫组化(IHC)是一种易于获得且相对廉价的技术,可检测这种癌症亚型,患者可从积极的治疗方案中获益。本研究的目的是评估CK5/6和CK14在乳腺癌中的表达及其与年龄、肿瘤分级、肿瘤大小、组织形态学模式、淋巴结状态、ER、PR、HER2/neu和Ki-67指数的相关性。
50例未经治疗且接受手术的乳腺癌患者组成研究组。未纳入粗针穿刺活检标本。对CK5/6、CK14、ER、PR、HER2/neu和Ki-67进行组织病理学检查及免疫组化。使用SPSS 20版软件对CK5/6和CK14的表达与年龄、肿瘤大小、肿瘤分级、组织学亚型、淋巴结状态、ER、PR、HER2/neu和Ki-67表达进行比较。
26%的病例显示CK5/6和CK14表达。CK5/6和CK14表达与ER/PR阴性、年轻以及Ki-67增殖指数大于15%密切相关。未显示与HER2/neu阴性有显著关联。CK5/6和CK14在肿瘤分级和淋巴结状态方面的表达结果相反。
免疫组化可用于以良好的敏感性和特异性识别基底型乳腺癌患者,此类患者可从积极治疗中获益。